Skip to content

Xencor XNCR Debt-to-assets

Debt-to-assets at other companies

Amgen logo
AmgenAMGN
0.6×0.0×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
0.1×0.0×
Janux Therapeutics logo
Janux TherapeuticsJANX
0.0×
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
0.1×+0.1×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
0.0×

Other financials

Income statement

See full
Revenue$4.5M-86.2%
Operating income-$77.9M-80.3%
Net income-$128.9M-166%
EPS (diluted)-$1.71-159%

Balance sheet

See full
Cash & equivalents$14.2M-64.3%
Total debt$175.2M-21.2%
Total equity$515.6M-19.4%
Total assets$736.8M-18.6%

Cash flow

See full
Operating cash flow-$67.6M-317%
CapEx$610.0K-57.8%
Free cash flow-$68.2M-286%

Valuation

See full
Market cap$1.07B+76.3%
Enterprise value$1.23B+55.9%
P/S11×+6.2×

Profitability

See full
Operating margin-217.9%+425pp
Net margin-177.1%+16.5pp
FCF margin-194%+166pp

Returns & leverage

See full
Return on equity-29.8%-2.7pp
Debt / equity0.3×0.0×
Current ratio6.6×+0.7×

Where this comes from

Calculated from Xencor’s reported figures.

Based on the most recent quarter.

The official record: Xencor’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xencor's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xencor's debt-to-assets?
Xencor (XNCR) reported debt-to-assets of 0.2× in Q1 2026.
How has Xencor's debt-to-assets changed year-over-year?
Xencor's debt-to-assets decreased by 3.2% year-over-year, from 0.2× to 0.2×.
What is the long-term trend for Xencor's debt-to-assets?
Over 5 years (2020 to 2025), Xencor's debt-to-assets has grown at a 67.0% compound annual growth rate (CAGR), from 0× to 0.2×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.